Trial Profile

A clinical study of Ketamir-2 for Major depressive disorder and Post-traumatic stress disorders

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 22 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ketamine analogue MIRA Pharmaceuticals (Primary)
Indications Major depressive disorder; Post-traumatic stress disorders
Focus Adverse reactions

Most Recent Events

20 May 2024 According to Mira Pharmaceuticals media release, the company expects to initiate this trial in 2025.
03 Apr 2024 New trial record
02 Apr 2024 According to Mira Pharmaceuticals media release, company plans to file an IND application with the US FDA for Major depressive disorder and Post-traumatic stress disorders by the end of 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com